This multicenter study randomized 1063 patients to receive the sirolimus-eluting stent with absorbable polymer and 1056 patients to permanent polymer stent. No differences in stent thrombosis (3.4% in the group with permanent polymer versus 2.8% in the group with absorbable polymer), target vessel revascularization (6.7% for both) or mortality (2.1% versus 2.9%; p = 0.7).<a href="https://solaci.org/en/2015/06/24/bioscience-study-absorbable-polymer-versus-permanent-in-sirolimus-eluting-stents/" title="Read more" >...</a>

The benefit of myocardial revascularization (angioplasty or surgery) guided by fractional flow reserve (FFR) in the context of acute coronary syndromes is poorly studied in the literature. The aim of this study was to compare myocardial revascularization guided by FFR versus Angiography in patients admitted suffering a non-ST segment elevation myocardial infarction. 350 patients were<a href="https://solaci.org/en/2015/06/24/famous-nstemi-ffr-versus-angiography-in-non-st-segment-elevation-myocardial-infarction/" title="Read more" >...</a>

The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a problem not yet solved same for all drug-eluting stents. The Absorb (Abbott Vascular, Abbott Park, IL, USA) is the first absorbable vascular support approved for clinical use. The EVERBIO II study<a href="https://solaci.org/en/2015/06/24/everbio-ii-bio-absorbable-stent-absorb-versus-everolimus-eluting-or-biolimus-stents/" title="Read more" >...</a>

The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific types of stents is unclear. This study aimed to evaluate the clinical non-inferiority at 3 months versus 12 months of dual anti-platelet therapy in patients undergoing coronary angioplasty with zotarolimus-eluting stents. The study randomized 1:1 to 3 months<a href="https://solaci.org/en/2015/06/24/optimize-3-months-versus-12-months-of-dual-anti-aggregation-with-zotarolimus-eluting-stents/" title="Read more" >...</a>

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences clinical outcomes after angioplasty and if the time of double anti-aggregation should be different with the degradable polymer. This work, with non-inferiority design, aimed to compare the sirolimus-eluting biodegradable polymer stent (Tivoli) versus the permanent polymer sirolimus-eluting stent<a href="https://solaci.org/en/2015/06/24/i-love-it2-drug-eluting-stents-with-a-permanent-polymer-versus-biodegradable-in-the-same-cobalt-chromium-platform/" title="Read more" >...</a>

The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB / IIIA glycoprotein in reducing adverse clinical events in patients suffering an ST-segment elevation myocardial infarction undergoing primary angioplasty, at the expense of increase in the rate of acute stent thrombosis. This study included 2194 patients undergoing an<a href="https://solaci.org/en/2015/06/24/bright-bivalirudin-versus-heparin-versus-heparin-plus-tirofiban-in-primary-angioplasty/" title="Read more" >...</a>

Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute coronary syndrome, especially if the patient has received coronary angioplasty. Few data are available in the real world in terms of safety and efficacy of prasugrel versus clopidogrel in this clinical context. This registry involved 12227 patients undergoing<a href="https://solaci.org/en/2015/06/24/translate-acs-one-year-prasugrel-versus-clopidogrel-after-acute-coronary-syndrome/" title="Read more" >...</a>

There are clinics hypothesis that systemic hypothermia (&le;34.9) could reduce infarct size if set before reperfusion. Peritoneal lavage had a well-established safety profile and given the large surface area of the bowel may cause rapid hypothermia reducing infarct size. The aim of this study was to evaluate the safety and efficacy of hypothermia induced by<a href="https://solaci.org/en/2015/06/24/velocity-peritoneal-hypothermia-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

While the use of intravascular ultrasound (IVUS) during coronary intervention proved useful in multiple studies, there is limited evidence in the literature regarding its use in specifically in chronic total occlusions. The IVUS may help guide in recognizing the true lumen and better distal positioning, better coverage of stent, an optimal apposition and expansion, diagnose<a href="https://solaci.org/en/2015/06/24/cto-ivus-ivus-clinical-impact-in-total-occlusions-with-2nd-generation-des/" title="Read more" >...</a>

This randomized, controlled, multicenter and blind study compared the second generation of bio-absorbable stent platform with the everolimus-eluting Xience. 501 patients were randomized 2: 1 (Absorb / Xience) with de novo lesions in native coronary arteries with a reference diameter between 2.25 and 3.8 mm estimated by quantitative angiography. All the patients underwent IVUS and<a href="https://solaci.org/en/2015/06/24/absorb-2-results-at-one-year-of-bioabsorbable-platform-versus-xience/" title="Read more" >...</a>